NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Clinical Trials Week


Susan Hasty, Publisher
Table of Contents . . . April 6th, 2009
Non-Subscriber - Summaries Only
Related Areas: Other Issues in Clinical Trials Week | Other Publications

Multiple Sclerosis - Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)

Breast Cancer - Research from G. Schilling and co-authors reveals new findings on breast cancer

Cancer - Investigators at University of Texas zero in on cancer

Cancer Vaccines - Study data from Columbia University provide new insights into cancer vaccines

Enzyme Research - Research from University of Liverpool has provided new information about enzyme research

Hepatocellular Cancer - Scientists at Medical University of South Carolina publish new data on hepatocellular cancer

Non-Small Cell Lung Cancer - Researchers at Chiba University target non-small cell lung cancer

Osteonecrosis - Findings from National Institutes of Health broaden understanding of osteonecrosis

Ovarian Cancer - Study findings from K.K. Zorn et al broaden understanding of ovarian cancer

Pharmacokinetics - Study data from R.J. Keizer and colleagues update understanding of pharmacokinetics

Tuberous Sclerosis - Data from Cardiff University advance knowledge in tuberous sclerosis

Breast Cancer Therapy - Data on breast cancer therapy published by G. Mustacchi and colleagues

Breast Cancer Therapy - Research from Henry Dunant Hospital, Department of Medical Oncology has provided new data on breast cancer therapy

Breast Cancer Therapy - Researchers at College of Medicine, Department of Oncology publish new data on breast cancer therapy

Chemotherapy - New chemotherapy study findings recently were published by researchers at University of Milan

Dialysis - Reports summarize dialysis research from B. Bernieh and co-authors

DNA Research - New DNA research study findings have been reported by scientists at Massachusetts Institute of Technology, Department of Chemical Engineering

Enzyme Research - Researchers from Bristol-Myers Squibb Company, Division of Molecular Biosciences provide details of new studies and findings in the area of enzyme research

Esophageal Cancer Therapy - New findings from Nanjing Medical University, Department of Medical Oncology in the area of esophageal cancer therapy described

Immunotherapy - New immunotherapy findings from Zurich University, Department of Dermatology published

Pancreatic Cancer Therapy - Findings from University Hospital in pancreatic cancer therapy reported

Soft Tissue Sarcoma Clinical Trial - New soft tissue sarcoma clinical trial study findings have been reported by researchers at Kyushu University, Department of Orthopaedic Surgery

Advaxis, Incorporated - Advaxis Updates Phase I Trial Survival Data: 23% of Patients Still Surviving after 2+ Years

Allos Therapeutics, Inc. - Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

AngioChem - AngioChem’s ANG1005 Shows Promise In the Treatment of Brain Cancers

Antares Pharma, Inc. - Antares Pharma Reports Fourth Quarter and Year End 2008 Financial and Operating Results

ArQule, Inc. - ArQule Enrolls First Patient in Phase 1 Trial with ARQ 621, an Eg5 Inhibitor

Bioengineering - Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel

Biopharmaceuticals - DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation

Cancer - Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial

Cancer Vaccines - ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs

Clinical Trial Research - Neuromed Announces Exalgo(TM) (hydromorphone HCl) Extended-Release Tablets (CII) Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial

Clinical Trial Research - Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing

Daiichi Sankyo Europe GmbH - Edoxaban - Factor Xa Inhibitor Enters Phase III With Optimal Dose

Drug Resistance - Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity

Endocyte Inc. - Endocyte Announces Positive Interim Results from Phase II Clinical Trial of EC145 in Patients with Advanced Non-Small Cell Lung Cancer NSCLC

Endometriosis - Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain

Gilead Sciences, Inc. - Gilead Initiates Phase II Clinical Trial of Cicletanine for the Treatment of Pulmonary Arterial Hypertension

GlycoMimetics, Inc. GMI - GlycoMimetics, Inc. Completes Phase 1 Clinical Studies of Lead Drug Candidate

Heart Failure - Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session

Ischemix - Ischemix Appoints Robert DuFresne as Chief Executive Officer

Lantheus Medical Imaging, Inc. - Lantheus Medical Imaging to Present New Cardiac Imaging Data at the American College of Cardiology 58th Annual Scientific Sessions in Orlando

Lupus - Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)

McMaster University - TB vaccine developed at McMaster University in Canada

Medgenics - Medgenics' Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients

Menopause - Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes

Neurotech Pharmaceuticals, Inc. - Positive Results from Neurotech’s NT-501 Phase 2 Dry AMD Geographic Atrophy Study Demonstrate Proof of Concept

Ovarian Cancer - Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer

Pharmaceuticals - Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference

Pharmaceuticals - Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine 'Notable People in R&D'

Reata Pharmaceuticals, Inc. - Reata Completes Financing and Expands Team to Capture Opportunity Created by Encouraging Clinical Data in Chronic Kidney Disease

RegeneRx Biopharmaceuticals, Inc. - RegeneRx Reports Phase II Venous Stasis Trial Results

Rexahn Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. RNN Initiates Phase II Pancreatic Cancer Clinical Trial

Sickle Cell Anemia - Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

Vertex Pharmaceuticals Incorporated - Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis

ZIOPHARM Oncology, Inc. - ZIOPHARM Reports Fourth Quarter and Full Year 2008 Financial Results



Return to Top of Page

-----------------------
PR Login